Ghana Pharmaceuticals and Healthcare Report Q2 2016

80 pages report Published in
Pharmaceuticals
Publisher: Business Monitor International

arrowFor This Report

BMI View: The Ghanaian government is actively making progress towards fulfilling its ambition of being
the Economic Communities of West African States (ECOWAS) hub for pharmaceutical and healthcare
investment. Domestic drugmakers are in a favourable position to take advantage of the growing regional
demand for medicines, while the government, in association with foreign aid agencies, is continuing to
upgrade local export capacities. The larger domestic manufacturers will look to gain WHO certification
and fulfilment of export potential needs for Good Manufacturing Practice certification. This would allow
Ghana to reduce its unsustainable reliance on imported pharmaceuticals, however cheaper generic imports
threaten the competitiveness of Ghanaian domestic drug manufacturers on a domestic and regional scale.
Headline Expenditure Projections
Pharmaceuticals: GHS1.18bn (USD311mn) in 2015 to GHS1.37bn (USD340mn) in 2016; +16.3% in local
currency terms and +9.5% in US dollar terms. Forecast unchanged from Q116.
Healthcare: GHS6.60bn (USD1.74bn) in 2015 to GHS7.47bn (USD1.86bn) in 2016; +13.3% in local
currency terms and +6.6% in US dollar terms. Forecast in line with Q415.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Ghana 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Ghana 2012-2020) 14
Healthcare Market Forecast 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Ghana 2012-2020) 17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Ghana 2012-2020) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Ghana 2012-2020) 18
Prescription Drug Market Forecast 19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Ghana 2012-2020) 20
Patented Drug Market Forecast 21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Ghana 2012-2020) 23
Generic Drug Market Forecast 24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Ghana 2012-2020) 25
OTC Market Forecast 26
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Ghana 2012-2020) 27
Pharmaceutical Trade Forecast 28
Table: Pharmaceutical Trade Data And Forecasts (Ghana 2014-2020) 31
Table: Pharmaceutical Trade Data And Forecasts Local Currency (Ghana 2014-2020) 31
Industry Risk/Reward Index 32
Middle East and Africa Risk/Reward Index - Q2 2016 32
Ghana Risk/Reward Index 39
Rewards 39
Risks 40
Regulatory Review 42
Intellectual Property Issues 43
Pricing And Reimbursement Regime 44
Market Overview 47
Healthcare Sector 48
Table: Healthcare Resources (Ghana 2010-2015) 51
Table: Healthcare Personnel (Ghana 2010-2015) 51
Table: Healthcare Activity (Ghana 2010-2015) 52
Research & Development 52
Clinical Trials 52
Epidemiology 54
Competitive Landscape 57
Research-Based Industry 57
Table: Multinational Market Activity 59
Generic Drugmakers 60
Pharmaceutical Distribution 60
Pharmaceutical Retail Sector 61
Company Profile 62
Ayrton Drug Manufacturing Company (Adcock Ingram) 62
Danadams 65
Demographic Forecast 69
Table: Population Headline Indicators (Ghana 1990-2025) 70
Table: Key Population Ratios (Ghana 1990-2025) 70
Table: Urban/Rural Population & Life Expectancy (Ghana 1990-2025) 71
Table: Population By Age Group (Ghana 1990-2025) 71
Table: Population By Age Group % (Ghana 1990-2025) 72
Glossary 74
Methodology 76
Pharmaceutical Expenditure Forecast Model 76
Healthcare Expenditure Forecast Model 76
Notes On Methodology 77
Risk/Reward Index Methodology 78
Index Overview 79
Table: Pharmaceutical Risk/Reward Index Indicators 79
Indicator Weightings 80

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (Ghana 2014-2020)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Ghana 2012-2020)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Ghana 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Ghana 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Ghana 2012-2020)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Ghana 2012-2020)
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Ghana 2012-2020)
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Ghana 2012-2020)
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Ghana 2012-2020)
Table: Pharmaceutical Trade Data And Forecasts (Ghana 2014-2020)
Table: Pharmaceutical Trade Data And Forecasts Local Currency (Ghana 2014-2020)
Table: Healthcare Resources (Ghana 2010-2015)
Table: Healthcare Personnel (Ghana 2010-2015)
Table: Healthcare Activity (Ghana 2010-2015)
Table: Multinational Market Activity
Table: Population Headline Indicators (Ghana 1990-2025)
Table: Key Population Ratios (Ghana 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Ghana 1990-2025)
Table: Population By Age Group (Ghana 1990-2025)
Table: Population By Age Group % (Ghana 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators

Related Reports

  • Kuwait Pharmaceuticals and Healthcare Report Q3 2015BMI View: While the losses incurred by Yiaco, the largest drug distributor in Kuwait, highlight a deteriorated near-term operating environment, with markedly lower prices as a result of the ongoing Gulf Cooperation Council (GCC) medicine price unification process, drugmakers will continue to perceive high long-run returns. Exhibiting a high and very costly burden of diabetes and cardiovascular conditions, Kuwait's aging population will continue to receive rising access to quality […]
  • Ghana Pharmaceuticals and Healthcare Report Q3 2014BMI View: Continuing depreciation in the Ghanaian currency has led us to revise our headline forecasts in USD for the pharmaceutical sector downwards. In the long-term however we remain positive for the sector with the government's focus on domestic pharmaceutical sector, greater foreign pharmaceutical company interest in the country and capacity building initiatives for bringing global quality control standards to Ghanaian pharmaceutical industry will spur domestic demand and […]
  • Belarus Pharmaceuticals and Healthcare Report Q2 2016BMI View: Government initiatives to boost the nascent domestic pharmaceutical industry and reduce the reliance on imports will limit the attractiveness of Belarus to multinational drugmakers. Government interference, in the form of domestic bias in the medicine tendering process and pricing controls, will further reduce revenue earning opportunities. Additional risks include a continued poor economic forecast and rising regional geopolitical tensions. Headline Expenditure […]
  • Cote d’Ivoire Pharmaceuticals and Healthcare Report Q2 2015BMI View: The launch of Côte d'Ivoire's universal healthcare scheme will improve much of the population's access to medicines and drive the demand for pharmaceuticals in the country. Its geographical proximity to Ebola-stricken Liberia and Guinea has seen the West African country be the beneficiary of aid donations which should assist in the strengthening of Côte d'Ivoire's health services. We highlight low affordability levels among the population as a barrier to healthcare […]
  • Sudan and South Sudan Pharmaceuticals and Healthcare Report Q2 2015BMI View: Access to healthcare in Sudan and South Sudan is poor and drug shortages are commonplace. The state is also heavily reliant on importing its medicines, though over the long-term we believe this reliance will decrease as the government is committed to developing domestic pharmaceutical production. Headline Expenditure Projections ? Pharmaceuticals: SDG2.06bn (USD353mn) in 2014 to SDG2.37bn (USD387mn) in 2015; +15.0% in local currency terms and +9.8% in US dollar terms. […]